-
CD ROM
-
Hard Copy
-
Electronic (PDF)
-
Enterprisewide
Optimizing Treatment for Metastatic Clear Cell Renal Cell Carcinoma: US Oncologist Survey
The Assessment Group, February 2011, Pages: 29
Two patient specific case scenarios that unfold throughout the report, presented to 119 high-prescribing oncologists on Metastatic Clear Cell Renal Cell Cancer for their open responses on clinical decisions. Patient progression reveals decisions in treatment throughout patient stages, factors influencing their decisions, barriers to optimal care, and confidence in treatment.
Patients include:
1) Elderly patient with good prognosis metastatic clear cell carcinoma
2) Clear cell carcinoma and comorbidities
Data has been synthesized to show the highest reported responses, “other” responses, and direct quotes from the oncologists. This is the primary research for the oncology prescribing data that you are missing - directly from high-prescribing US oncologists on Metastatic Clear Cell Renal Cell Cancer.
Treatment decisions for advanced stages of renal cell cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists' choices. This report is part of a series of oncology reports that allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer.
This report allows you to:
- Understand what occurs with actual patients
- Access the most up-to-date prescribing trends
- Gain actionable data for developing and improving your market strategies
- Pinpoint needs of your target audience
- Focus resources to maximize the effectiveness of your budget
- Understand where your product fits
- Understand where your competitor's product fits
- Design messages to advance brand performance
Executive Summary
Chapter 1: Introduction
Table 1. Treatment Options in Renal Cell Cancer
Chapter 2. Survey Respondent Demographics
Table 2. Eligibility Criteria for Survey Participation
Figure 2.1 Gender of Survey Respondents
Figure 2.2 Years since Medical School Graduation
Figure 2.3 Practice Settings
Figure 2.4 Practices in NCI Cancer Centers
Figure 2.5 Geographic Settings
Figure 2.6 Survey Respondents by State's Renal Cell Cancer Mortality
Figure 2.7 Number of Physicians in Practice Groups
Figure 2.8 Minimal Acceptable Level of Evidence in Determining Treatment Regimen
Chapter 3: Treatment of an Elderly Patient with Metastatic Clear Cell Renal Cell Carcinoma
Figure 3.1 Treatment Regimen Chosen Following Surgery
Figure 3.2 Adding Therapeutic Agents with Initial Treatment
Figure 3.3 Treatment Decision for Medication Toxicity
Figure 3.4 Second-Line Therapy
Figure 3.5 Factors Influencing Treatment
Figure 3.6 Confidence in Managing Clear Cell Renal Cell Carcinoma
Figure 3.8 Most Important Barrier to Optimal Patient Management
Chapter 4. Treatment of a Patient with Metastatic Clear Cell Renal Cell Carcinoma with Comorbidities
Figure 4.1 Management of Patient with Metastatic Disease and Comorbidities
Figure 4.2 Choice of Systemic Therapy Agent
Figure 4.3 Test to Monitor to Evaluate Increased Fatigue with Pazopanib
Figure 4.4 Next Systemic Treatment Choice for Progressive Disease
Chapter 5: Summary
Appendix A: Survey Instrument
- Novartis
- Genentech
- Onyx
- Bayer
- Pfizer
- GlaxoSmithKline
- Amgen
Product Samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
